Drug profile

The FDA adverse-event record for Yohimbine

17 FDA reports name Yohimbine, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1993 of 2,679
by report volume (all drugs)
17
adverse-event reports
41.2%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Yohimbine ranks #1937 of 2679 by total reports (17). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1937
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Yohimbine has 17 reports now versus 17 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Yohimbine changes

Signature read: Yohimbine's 41.2% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
7
Deaths Reported
41.2%
Death-coded share of reports

Active Ingredients

Yohimbine

Administration Routes

UnknownParenteralIntravenousSubcutaneousIntramuscular

Species Affected

Dog 8
Cat 7
Other Birds 1
Mouse 1

Most Affected Breeds

Domestic Shorthair 3
Retriever - Labrador 2
Crossbred Canine/dog 2
Dachshund (unspecified) 2
Cat (unknown) 2
Other Birds (other) 1
Unknown 1
Domestic Longhair 1
Mixed (Cat) 1
Pit Bull 1

Most Reported Reactions

Death 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Emesis 4
Other abnormal test result NOS 3
Hives (see also 'Skin') 3
Tachycardia 2
Recumbency 2
Fever 2
Death by euthanasia 2
Sedation 2
Seizure NOS 2
Hyperthermia 2

Outcome Breakdown

Recovered/Normal
11 (61.1%)
Died
6 (33.3%)
Euthanized
1 (5.6%)

Yohimbine: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Yohimbine (#1993 of 2,679 by report volume); death-coded 41.2%. PlainBreed drug row · death-coded share stamp 41.2% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →